Business · 25/01/2024
FDA Releases Final Guidance on Revised Abbreviated New Drug Application Labeling
The US Food and Drug Administration (FDA) has released a final guidance for industry on revising labeling for abbreviated new drug applications (ANDAs) following revisions to the labeling of reference listed drugs (RLDs).
Original source language: Federal Register — Food and Drug AdministrationOpen original release →